News · 26 weeks53+33%
2026-03-012026-08-23
Mix2090d
- Insider7(35%)
- Other5(25%)
- SEC Filings4(20%)
- Analyst2(10%)
- Earnings1(5%)
- Offering1(5%)
Latest news
25 items- PRNektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic DermatitisREZOLVE-AD study met all primary and key secondary endpoints, including EASI-75, EASI-90, Itch NRS, vIGA-AD and BSA, on rezpegaldesleukin 24 µg/kg q2wFirst large, placebo-controlled trial to support T-reg modulation as a clinical mechanism for immunoregulation of chronic inflammatory diseaseFindings support the continued development of rezpegaldesleukin in the ongoing Phase 3 ZENITH AD clinical programSAN FRANCISCO, Aug. 25, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced the publication of peer-reviewed data from the 16-week induction period of REZOLVE-AD, a global, randomized, double-blind, placebo-controlled Phase 2b study evaluating rezpegaldesleukin in adults with
- ANALYSTAnalyst resumed coverage on Nektar Therapeutics with a new price targetAnalyst resumed coverage of Nektar Therapeutics with a rating of Neutral and set a new price target of $65.00
- INSIDERChief R&D Officer Zalevsky Jonathan sold $13,388 worth of shares (186 units at $71.98), decreasing direct ownership by 2% to 9,570 units (SEC Form 4) (withholding obligation)4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- INSIDERPresident & CEO Robin Howard W sold $30,088 worth of shares (418 units at $71.98), decreasing direct ownership by 0.76% to 54,627 units (SEC Form 4) to satisfy tax liability4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- SECSEC Form S-8 filed by Nektar TherapeuticsS-8 - NEKTAR THERAPEUTICS (0000906709) (Filer)
- SECSEC Form 10-Q filed by Nektar Therapeutics10-Q - NEKTAR THERAPEUTICS (0000906709) (Filer)
- SECNektar Therapeutics filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - NEKTAR THERAPEUTICS (0000906709) (Filer)
- PRNektar Therapeutics Announces Second Quarter 2026 Financial ResultsSAN FRANCISCO, Aug. 13, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today reported financial results for the second quarter ended June 30, 2026. Cash and investments in marketable securities on June 30, 2026, were $1,023.4 million as compared to $245.8 million on December 31, 2025. "This year continues to be a transformative year for Nektar as we advance our lead program, rezpegaldesleukin, into Phase 3 clinical trials," said Howard W. Robin, President and Chief Executive Officer of Nektar. "We initiated the first Phase 3 ZE
- PRNektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial MarketsSAN FRANCISCO, July 28, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter ended June 30, 2026 on Thursday, August 13, 2026, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: https://ir.nektar.com/. The web broadcast of the confere
- INSIDERSEC Form 4 filed by Chief R&D Officer Zalevsky Jonathan4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- INSIDERSEC Form 4 filed by President & CEO Robin Howard W4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- PRNektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN FRANCISCO, July 24, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced that, on July 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 36,000 shares of its common stock to twenty-three newly-hired employees under Nektar's 2025 Inducement Plan. Nektar's 2025 Inducement Plan was adopted by its Board of Directors on November 6, 2025 and is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Nektar (or following a bona fide period of non
- ANALYSTCanaccord Genuity initiated coverage on Nektar Therapeutics with a new price targetCanaccord Genuity initiated coverage of Nektar Therapeutics with a rating of Buy and set a new price target of $153.00
- PRNektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic DermatitisTwo global registrational Phase 3 trials initiated in ZENITH AD programPhase 3 program based upon clinically meaningful efficacy and favorable safety data observed in 393-patient Phase 2b study with monthly and quarterly maintenance dosing, including an up to five-fold increase in EASI-100 between 16 and 52 weeksZENITH AD program includes these first two 510-patient studies in patients who are systemic biologic/JAK inhibitor treatment-naive (ZENITH AD-1 and ZENITH AD-2) and one 510-patient study in patients who are treatment-experienced (ZENITH AD-3), which will begin in SeptemberInitial Phase 3 topline data expected in mid-2028 with BLA submission targeted for 2029SAN FRANCISCO, July 21, 20
- INSIDERChief R&D Officer Zalevsky Jonathan sold $397,670 worth of shares (5,681 units at $70.00) as part of a pre-agreed trading plan, decreasing direct ownership by 37% to 9,756 units (SEC Form 4)4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- PRNektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN FRANCISCO, June 26, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced that, on June 19, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 20,500 shares of its common stock and 3,900 restricted stock units (RSUs) to seven newly-hired employees under Nektar's 2025 Inducement Plan. Nektar's 2025 Inducement Plan was adopted by its Board of Directors on November 6, 2025 and is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Nektar (or fo
- INSIDERPresident & CEO Robin Howard W sold $1,215,056 worth of shares (20,000 units at $60.75) as part of a pre-agreed trading plan, decreasing direct ownership by 27% to 55,045 units (SEC Form 4)4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- INSIDERChief R&D Officer Zalevsky Jonathan sold $336,212 worth of shares (5,538 units at $60.71) as part of a pre-agreed trading plan, decreasing direct ownership by 26% to 15,437 units (SEC Form 4)4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- SECNektar Therapeutics filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - NEKTAR THERAPEUTICS (0000906709) (Filer)
- PRNektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN FRANCISCO, June 3, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced that, on May 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 11,900 shares of its common stock to five newly-hired employees under Nektar's 2025 Inducement Plan. Nektar's 2025 Inducement Plan was adopted by its Board of Directors on November 6, 2025 and is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Nektar
- PRNektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New YorkSAN FRANCISCO, May 27, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced that company management will be webcasting its participation in the 2026 Jefferies Global Healthcare Conference being held June 2-4, 2026 in New York. 2026 Jefferies Global Healthcare Conference in New York on Wednesday, June 3, 2026 – webcast to be available at 1:20 p.m. Eastern Time – webcast link hereThe fireside chat will be accessible via the webcast link above as well as on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-presentations/events. A
- INSIDERSEC Form 3 filed by new insider Rubinstein Linda M3 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- INSIDERChief R&D Officer Zalevsky Jonathan sold $13,036 worth of shares (199 units at $65.51), decreasing direct ownership by 0.94% to 20,975 units (SEC Form 4) (withholding tax)4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- INSIDERPresident & CEO Robin Howard W sold $29,086 worth of shares (444 units at $65.51), decreasing direct ownership by 0.59% to 75,045 units (SEC Form 4) (tax withholding)4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Nektar TherapeuticsSCHEDULE 13G/A - NEKTAR THERAPEUTICS (0000906709) (Subject)
NKTR FAQ
6 questionsWhat does Nektar Therapeutics do?
Nektar Therapeutics operates as a biopharmaceutical company. The company researches and develops pipeline of investigational medicines in oncology, immunology, and virology, as well as a portfolio of approved partnered medicines. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma and urothelial cancer; phase 1/2A clinical trial to...Where does NKTR stock trade?
Nektar Therapeutics (NKTR) is listed on NASDAQ.What sector and industry is NKTR in?
Nektar Therapeutics operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about NKTR?
Nektar Therapeutics has had 8 recent analyst actions on file. The most recent action was from Analyst: Neutral on 2026-08-21.What companies are similar to NKTR?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare NKTR side-by-side with any of them on Quantisnow.How can I track NKTR on Quantisnow?
Quantisnow aggregates Nektar Therapeutics's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NKTR to receive live email and push alerts on every new disclosure.